Immunic Q2 EPS $(0.21) Beats $(0.24) Estimate, Exits Quarter With Cash & Equivalents Worth $79.698M
Portfolio Pulse from Benzinga Newsdesk
Immunic (NASDAQ:IMUX) reported a Q2 EPS of $(0.21), beating the analyst estimate of $(0.24). The company also exited the quarter with $79.698M in cash and equivalents. This represents a significant improvement from the $(0.54) per share loss in the same period last year.
August 08, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunic reported a Q2 EPS of $(0.21), beating the analyst estimate of $(0.24). The company also exited the quarter with $79.698M in cash and equivalents. This represents a significant improvement from the $(0.54) per share loss in the same period last year.
The better-than-expected EPS and significant improvement from the previous year's loss are positive indicators for the company's financial health. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100